Krishnamoorthy, J., Rajesh, K., Mirzajani, F., Kesoglidou, P., Papadakis, A. I., & Koromilas, A. E. (2014). Evidence for eIF2α phosphorylation-independent effects of GSK2656157, a novel catalytic inhibitor of PERK with clinical implications. Landes Bioscience.
Chicago Style CitationKrishnamoorthy, Jothilatha, Kamindla Rajesh, Farzaneh Mirzajani, Polixenia Kesoglidou, Andreas I. Papadakis, i Antonis E. Koromilas. Evidence for EIF2α Phosphorylation-independent Effects of GSK2656157, a Novel Catalytic Inhibitor of PERK With Clinical Implications. Landes Bioscience, 2014.
Cita MLAKrishnamoorthy, Jothilatha, et al. Evidence for EIF2α Phosphorylation-independent Effects of GSK2656157, a Novel Catalytic Inhibitor of PERK With Clinical Implications. Landes Bioscience, 2014.